A novel TRPS1 gene mutation causing trichorhinophalangeal syndrome with growth hormone responsive short stature: a case report and review of the literature by Lina Merjaneh et al.
Merjaneh et al. International Journal of Pediatric Endocrinology 2014, 2014:16
http://www.ijpeonline.com/content/2014/1/16CASE REPORT Open AccessA novel TRPS1 gene mutation causing
trichorhinophalangeal syndrome with growth
hormone responsive short stature: a case report
and review of the literature
Lina Merjaneh*, John S Parks, Andrew B Muir and Doris FadojuAbstract
The role of growth hormone (GH) and its therapeutic supplementation in the trichorhinophalangeal syndrome type
I (TRPS I) is not well delineated. TRPS I is a rare congenital syndrome, characterized by craniofacial and skeletal
malformations including short stature, sparse, thin scalp hair and lateral eyebrows, pear-shaped nose, cone shaped
epiphyses and hip dysplasia. It is inherited in an autosomal dominant manner and caused by haploinsufficiency of
the TRPS1 gene. We report a family (Mother and 3 of her 4 children) with a novel mutation in the TRPS1 gene. The
diagnosis was suspected only after meeting all family members and comparing affected and unaffected siblings since
the features of this syndrome might be subtle. The eldest sibling, who had neither GH deficiency nor insensitivity,
improved his growth velocity and height SDS after 2 years of treatment with exogenous GH. No change in growth
velocity was observed in the untreated siblings during this same period. This report emphasizes the importance of
examining all family members when suspecting a genetic syndrome. It also demonstrates the therapeutic effect of
GH treatment in TRPS I despite normal GH-IGF1 axis. A review of the literature is included to address whether TRPS I is
associated with: a) GH deficiency, b) GH resistance, or c) GH-responsive short stature. More studies are needed before
recommending GH treatment for TRPS I but a trial should be considered on an individual basis.
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Trichorhinophalangeal syndrome (TRPS) is a rare
malformation syndrome characterized by distinctive
craniofacial and skeletal abnormalities. It was first
described by Klingmuller in 1956 [1] and then named
the trichorhinophalangeal syndrome by Giedion in 1966
[2]. Three subtypes have been described. Features
common to all subtypes are sparse scalp hair and lateral
eyebrows, bulbous tip of the nose, long flat philtrum, thin
upper vermilion border and protruding ears. Skeletal
abnormalities include cone shaped epiphyses at the
phalanges, hip dysplasia (resembling but not identical
to Legg-Calve-Perthes disease) and short stature [3].
Patients with TRPS II have multiple cartilaginous* Correspondence: linamerjaneh@msn.com
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unless otherwise stated.exostoses in addition to the previous findings. The
presence of severe brachydactyly and severe short
stature with the absence of exostoses differentiates
TRPS III.
TRPS is inherited in an autosomal dominant manner
[4]. The TRPS1 gene maps to 8q24 [5,6] and encodes a
zinc finger transcription repressor involved in the
regulation of chondrocyte and perichondrium develop-
ment [7]. It has 2 potential nuclear localization signals and
9 different zinc-finger motifs [8,9]. Haploinsufficiency for
this putative transcription factor causes TRPS I [9]. Most
patients with nonsense mutations show the TRPS I
phenotype, while patients with missense mutations in the
GATA, DNA-binding, zinc-finger show the more severe
TRPS III phenotype [10]. TRPS II is a contiguous gene
deletion syndrome involving the EXT1 and TRPS1 genes
resulting in the additional finding of multiple exostoses.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Bone age radiograph of patient’s younger brother
showing the cone shaped epiphyses with diffuse shortening of
the phalanges.
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(GH) in patients with TRPS I has been inconsistent
according to previous reports. Naselli et al. and Sohn et al.
reported failure of GH treatment in a pair of monozygotic
twins and 2 other unrelated patients with TRPS I [11,12],
whereas Stagi et al. and Sarafoglou et al. reported that GH
treatment was effective in improving height velocity in 4
patients with TRPS I [13,14].
We report here a family with TRPS I with a novel non-
sense mutation in the TRPS1 gene. The mother and 3 of
her 4 children have clinical features of TRPS I. The eldest
sibling, who had normal GH secretion determined by
provocative testing, a normal GH-IGF-1 axis, and normal
bone mineral density (BMD), accelerated his linear growth
velocity over a 2 year GH treatment period.
Case presentation
The patient presented at age 7 years 2 months for
evaluation of short stature. He was born at term by
vaginal delivery with a birth weight of 3.373 kg. His
history was significant for severe gastroesophageal
reflux in infancy causing poor weight gain. He also
suffered from recurrent ear infections. At the age of 2 years,
he was diagnosed with atypical Legg-Calve-Perthes disease
in the left hip that did not require casting or surgery. His
height had been tracking below the first percentile
and his weight between the 10–25th percentile since age
3 years. Midparental height was 171 cm (25th percentile)
with a maternal height of 157.5 cm and paternal height of
172 cm.
At the time of the initial evaluation, the patient’s
height was 110.3 cm (1st percentile, −2.25 SD) and
weight was 22 kg (25–50th). Although no dysmorphia was
noted at that visit, suspicion for TRPS I subsequently
arose after other features of TRPS were identified in 2
affected siblings (younger brother and sister). The combined
features of TRPS I seen in the mother and 3 of her children
were: short stature, thin sparse scalp hair, long flat philtrum,
thin upper vermilion border, bulbous nose tip, high arched
narrow palate and overcrowded teeth. There was one
unaffected younger brother.
Initial laboratory evaluation (Quest Diagnostics,
Atlanta, GA) showed the following: TSH 2.13 uIU/mL
(nl: 0.5–4.5), Free T4 1.24 ng/dL (nl: 0.9–1.6), IGF1
180 ng/mL (nl: 37–217), IGFBP3 3.9 mg/L (nl: 1.4–6.1).
Bone age radiograph revealed the presence of normally-
shaped phalangeal epiphyses with a significantly delayed
bone age of 3 years 6 months (−4.3 SD). However, bone
age radiograph of his younger brother who was 5 years
old revealed the presence of cone-shaped phalangeal
epiphyses with diffuse shortening of the phalanges in
addition to delayed bone age of 2–3 years (−3.4 SD)
(Figure 1). Peak serum GH concentrations were
15.3 ng/mL after insulin and 8.2 ng/mL after arginine.Serum cortisol rose from 5.9 to 18.8 ug/dL as serum
glucose dropped to 43 mg/dL after insulin. Dual-energy
X-ray absorptiometry (DEXA) scan was normal with
whole body BMD of 0.87 g/cm2 (Z score 0.6) and spinal
BMD of 0.8 g/cm2 (Z score −0.1). Similarly, DEXA scan
of the younger sibling showed normal whole body BMD
of 0.78 g/cm2 (Z score 0.0) and borderline diminished
spinal BMD of 0.5 g/cm2 (Z score −1.4).
Gene sequencing (Prevention Genetics, Marshfield,
WI) of the patient and his younger affected brother
demonstrated heterozygosity for a nonsense mutation,
c.3368 G > A (p.Trp1123Stop).
Daily subcutaneous GH was administered for 2 years
beginning at age 8 years 4 months with a mean dose
of 0.28 mg/kg/week (Table 1). The height SDS score
increased from −2.4 to −1.4 and his growth velocity
increased from 4.7 cm/year before treatment to 7.7 cm/year
during treatment (Figure 2). Bone age advanced by 2.5 years
(from 4.5 to 7 years) during 2 years of GH treatment. He
remained prepubertal during treatment. In comparison, his
younger brother whose application for GH treatment was
denied remained below the 1st percentile for height with a
growth velocity of 5.5 cm/year during that time.
Discussion
TRPS I is an infrequently diagnosed cause of short
stature that is associated with subtle dysmorphia. It
displays clinical heterogeneity, even within a family.
In the case reported here, although the diagnosis was
Table 1 Growth data and GH dose in our patient
Chronological age (CA) Height (cm) Height Percentile/SDS Growth velocity (cm/year) Bone age (BA) GH dose (mg/kg/week)
7 y 2 m 110.3 1st/- 2.33 3 y 6 m 0
8 y 4 m 115.8 1st/- 2.38 4.7 4 y 6 m Started at 0.29
9 y 4 m 123.8 3rd/- 1.85 8 0.28
10 y 4 m 131.2 9th/1.39 7.4 7 y 0.27
SDS: Standard deviation score.
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3 affected siblings were combined that the diagnosis
was made.
Genetics and pathophysiology of TRPS I
Consistent with the TRPS I phenotype, cartilage and
hair follicles are among the limited tissues that express the
gene. It is postulated that TRPS1 (the protein product
of TRPS1) deficiency impairs endochondral cartilage
differentiation and epithelial/mesenchymal cell interac-
tions in developing hair follicles [15]. Mechanistically, it isFigure 2 Growth chart of patient before and after starting growth hormhypothesized that TRPS1 deficiency induces mitotic arrest
in prometaphase cells as a result of abnormal chromatin
condensation caused in part by excessive histone deacety-
lation [16]. Normally, TRPS1 homodimers complex with
GATA binding protein sequences in DNA to repress
transcription of target genes, an effect that is suppressed
when TRPS1 is complexed with either the dynein
light-chain LC8 or the ring finger protein RNF4.
Mutation analysis of TRPS1 has revealed that missense
mutations restricted to the GATA DNA-binding domains
(aa 886–952) caused the more severe musculoskeletalone. F: father’s height, M: mother’s height. MPH: midparental height.
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missense mutations occurred outside the GATA zinc
finger and in all reported nonsense single base pair
mutations, the milder TRPS I phenotype arose [17] as
in our case. The previously unreported mutation in
this family is predicted to stop translation between
the 7th and 8th zinc finger domains of TRPS1. In theory,
translation of the nuclear translocation signal persists, but
the mutation prevents extension of TRPS1 to the 2 Ikaros
family zinc fingers at the protein’s carboxy terminus.
These are necessary for repression of GATA-driven
transcriptional signals [18]. Although the mutation
also interrupts the RNF4 binding site between amino
acids 985 – 1184, this change should be inconsequential
in the absence of the Ikaros domains.
Ludecke et al. reported the average height of 75 patients
with TRPS to be 1.41 SD below the average height of the
respective population (SD = 1.15). Their data included
children and adults with TRPS I and III [10]. Four
previous reports of growth hormone treatment for
short stature in patients with TRPS I have yielded
conflicting results (Table 2). Naselli et al. first reported no
growth promotion by GH in monozygotic twins with
TRPS I [11]. Although the report indicated both children
had GH deficiency, the actual GH stimulation tests results
were not included. Prior to the start of growth hormone,
both girls were prepubertal and had bone age delays
of 2–3 years. Their treatment was discontinued after
12 months owing to its ineffectiveness.
Sohn et al. also reported 2 Korean patients with TRPS
I who were unresponsive to GH treatment [12]. One
was a 4 year old girl who was GH deficient based on
stimulation testing. Despite a 10 year course of GH
(0.2 mg/kg/week), her height SDS response to treatment
was not impressive as she only gained 0.4 SDS change in
her height over that time. The other was a 14 year old
boy with a bone age of 16 years and a peak circulating
GH concentration of 9.9 ng/mL after receiving glucagon.
He did not show any growth velocity response after a
6 month GH trial, a circumstance that is expected with
his advanced bone age of 16 years.
Stagi et al. [13] described 2 GH-responsive patients with
TRPS I who had normal GH responses to provocative
testing [13]. The authors however considered the patients
to both have partial growth hormone deficiency based on
low nocturnal mean GH concentrations. One had a height
SDS of −2.2 and a bone age of 9.5 years at age 12 years.
After 5 years of GH treatment, his adult height was −1.5
SDS, well above his mid-parental target height of −3.5
SDS. The other patient had a height SDS of −2.0 and bone
age of 7 years 8 months at age 9 years 9 months. His
growth velocity doubled during the first year of treatment
and his final height was −0.1 SDS. The rate of bone age
progression during GH treatment was not reported foreither patient and unfortunately, neither experienced
improvements of their pre-treatment osteopenia.
Sarafoglou et al. [14] described accelerated growth and
improved bone mineral density after GH treatment in 2
siblings with TRPS I [14]. A 6.3 year old male had a
height SDS of −2.7, weight SDS −3.6, pre-treatment
growth velocity of 2.5 cm/year, and bone age of 3.5 years.
In the face of normal GH provocative testing, his
serum IGF-1 concentration of 81 ng/mL was consid-
ered to indicate GH resistance, notwithstanding an
IGFBP3 concentration of 1.7 mcg/mL. Growth hormone
(0.3 – 0.43 mg/kg/week) for 3.2 years resulted in an
increased height SDS to −1.37, weight SDS −1.06, mean
growth velocity of 6.7 cm/year and bone age progression
to 8 years. This patient’s sister had a height SDS of −2.76,
weight SDS of −3.35 at 6.3 years, pre-treatment growth
velocity of 3.9 cm/year, and bone age of 5.75 years. She
too was designated as GH resistant on the basis of normal
provocative GH testing, serum IGF1 concentration of
81 ng/mL, and serum IGFBP3 concentration of 3.5 mg/L.
Over 3 years of GH treatment, her height SDS rose
to −1.1 and her bone age increased to 7.8 years. The
IGF1 concentrations of both children rose by 2 to 5 fold
over their baseline levels while they received exogenous
GH doses of 0.3 to 0.5 mg/kg/week. Improved BMD
was reported with GH treatment, but only in the female
patient.
Combined with the family reported here, the literature
allows a series of questions to be addressed.
Is short stature in TRPS I associated with GH deficiency?
The normal responses of growth hormone to insulin and
arginine in the child reported here are consistent with
previous reports that suggest classic GH deficiency is
not common among patients with TRPS I. Of the 6
published patients who underwent provocative GH
testing, 5 had normal responses and one had a peak
response of 5 ng/mL after L-dopa administration. The
inability of provocative GH testing to discern normal
from pathological states when the peak response falls
above 2.5 ng/mL is well described [19,20]. Stagi et al.
diagnosed partial GH deficiency in their patients based on
serial measurements of nocturnal serum growth hormone
concentrations. The reliability of this procedure is
questionable since its diagnostic usefulness was reported
to be inferior to stimulation testing [21].
Is TRPS I associated with GH resistance?
Although Sarafoglou et al. claimed their patients both
had GH resistance, the baseline serum IGF1 SDS scores
were −1.5 in both patients and these were accompanied
by normal IGFBP3 concentrations. With weight SDS
scores significantly below the height SDS scores, one
should consider the possibility that malnutrition in the
Table 2 Summary of the reports on GH axis evaluation and treatment in patients with TRPS I
Patients (gender) Genetic diagnosis GH status Chronological









Naselli et al. 1998 [11] Patient 1 (F) Not reported Deficient, based on GH stim test and IGF1
level, no data
11.1 y 8–9 y Prepubertal 0.23 None
Patient 2 (F) Not reported Deficient, based on GH stim test and IGF1
level, no data
11.1 y 8–9 y Prepubertal 0.23 None
Stagi et al. 2008 [13] Patient 3 (M) Not reported Partial deficiency, Peak after arginine 6.8, after
insulin 12.7, low nocturnal GH 2.7
12 y 9 y 6 m G2, PH2, T4 ml
bilaterally
0.26 + 0.7 SDS
over 5 years
Patient 4 (M) c2722C > T (p.R908X) Partial deficiency. Peak after Clonidine 10.2,
peak after insulin5.4, low nocturnal GH 2.38
9 y 9 m 7 y8 m Prepubertal 0.26 + 1.9 SDS
over 7 years
Sarafoglou et al. 2010 [14] Patient 5 (M) Not reported No deficiency. Low IGF1 and normal IGFBP3 7 y ~3 y delay Prepubertal 0.3–0.43 +1.81 SDS
over 3 years
Patient 6 (F) Not reported No deficiency. Low IGF1 and normal IGFBP3 6.95 y ~ 6 m delay Prepubertal 0.34–0.54 +1.95 SDS
over 2 years
Sohn et al. 2012 [12] Patient 7 (F) c2520dupT
(p.Arg841LysfsX3)
Deficient (peak after insulin 3.17 and after
L-dopa 5)
4 y 2.6 y Prepubertal 0.2 + 0.4 SD
over 10 years
Patient 8 (M) c1630C > T
(p.Arg544X)
Not deficient (peak after glucagon 9.86,
after L-dopa 9.7)
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sions of IGF-1. Nutritional counseling was not addressed
in the report. Finally, the marked increase of circulating
IGF1 after exogenous GH administration is inconsistent
with a GH resistant state. The normal pre-treatment
serum IGF1 and IGFBP3 concentrations in the children
reported here and their responses to exogenous GH
administration are also evidence against a growth hormone
resistant state.
Is short stature in TRPS I GH responsive?
Increased growth velocity and final height after GH
treatment are well described in short children with
normal function of their GH-IGF1 axis. The patient
reported here increased his growth velocity by 63 percent
over the 2 years of treatment. This compares to a mean
change in growth velocity of 66–168 percent among the
responding patients in the previously published reports.
The previous reports may indicate that the early initiation
of GH treatment is associated with better height out-
comes. Similar observations were reported after GH
treatment in children with GH-sufficient, idiopathic
short stature [22]. Sohn et al. however reported subopti-
mal growth in a girl with TRPS I, despite starting a 10 year
course of GH supplementation at 4 years of age [12].
Factors contributing to her poor response may include the
low GH dose (0.2 mg/kg/week), her midparental height,
and the adherence to her recommended treatment. A dose
dependent effect may be reflected in better outcomes
reported by Sarafoglou et al. [14] in 2 children receiving
GH doses of 0.3 to 0.5 mg/kg/week.
The mechanism by which growth hormone therapy
could accelerate linear growth in children with TRPS I is
unknown and could be complex. In a cell culture model
that may mimic TRPS1 mutations however, IGF-1 expres-
sion by a chondrogenic cell line derived from a murine
teratoma (ATDC5) was reduced by blockade of TRPS1
expression with microRNA [23]. It is therefore possible
that high systemic IGF-1 concentrations, resulting from
growth hormone therapy, compensate for low local IGF-1
concentrations in the growth plates of individuals with
TRPS1 mutations.
These cases also incidentally indicate the need to
consider whether routine evaluation of bone mineral
density is indicated in patients with TRPS I and whether it
may be increased by GH treatment.
Conclusions
We report here a family with TRPS I (the mother and 3
of her 4 children) caused by a novel mutation in the
TRPS1 gene. The older child was treated with growth
hormone for 2 years using a dose that ranged from 0.24
to 0.32 mg/kg/week. Despite the fact that he did not
have growth hormone deficiency or insensitivity, heshowed an excellent response to treatment with +1 SDS
gain in his height over 2 years.
At a time when GH treatment is becoming more difficult
to provide due to restrictions applied by insurance
companies, this report supports the consideration of
GH treatment for patients affected with TRPS I. Short
stature could be a contributing risk factor for psychosocial
problems in some children, such as social immaturity, low
self-esteem, and being bullied in addition to possible
disadvantages in terms of obtaining employment and
finding partners as adults [24-26]. More data are needed
before TRPS I can be considered an indication for GH
treatment, but our case proves that GH improves height
outcome in TRPS I in the short term. Effect on final adult
height will need longer follow-up of this patient until
adulthood. The appropriate advancement of bone age
during treatment suggests that his final height will not be
adversely affected with GH treatment.
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